side effects of glp-1 drugs Agonists: Using Semaglutide, Tirzepatide, and Orforglipron for Weight Loss and Obesity Ozempic and other GLP-1 drugs
Description
1.2 Current challenges in diabetes and obesity management Obesity and diabetes are becoming increasingly common worldwide, presenting serious challenges for public health that cannot be ignored
Tinsley GM et al
Research published in The Lancet examining GLP-1 receptor agonist eligibility across 99 countries found that eligibility varies dramatically based on which BMI thresholds are used
rarer risks include pancreatitis
Our study showed no differences for VitD and OCN at baseline between those with osteoporosis and without osteoporosis at follow-up
